Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Abstract Background Due to recent concerns about the toxicity of trastuzumab emtansine (T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-DM1 and stereotactic radiation. Methods This is a single institution...

Full description

Bibliographic Details
Main Authors: Matthew N. Mills, Chelsea Walker, Chetna Thawani, Afrin Naz, Nicholas B. Figura, Sergiy Kushchayev, Arnold Etame, Hsiang-Hsuan Michael Yu, Timothy J. Robinson, James Liu, Michael A. Vogelbaum, Peter A. Forsyth, Brian J. Czerniecki, Hatem H. Soliman, Hyo S. Han, Kamran A. Ahmed
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
Trastuzumab emtansine
Kadcyla
Breast cancer
Brain metastases
Stereotactic radiotherapy
Online Access:https://doi.org/10.1186/s12885-021-07971-w

Internet

https://doi.org/10.1186/s12885-021-07971-w

Similar Items